- Tuesday, May
18th – 2:00 p.m.
ET -
MISSISSAUGA, ON, May 11, 2021 /PRNewswire/ - Nuvo
Pharmaceuticals® Inc. (TSX: MRV) (OTCQX: MRVFF) d/b/a
Miravo Healthcare (Miravo or the Company), a Canadian focused
healthcare company with global reach and a diversified portfolio of
commercial products, today announced Jesse
Ledger, Miravo's President & Chief Executive Officer and
Mary-Jane Burkett, Miravo's Vice
President & Chief Financial Officer will be presenting at the
Q2 Virtual Investor Summit.
DATE:
|
Tuesday, May
18,, 2021
|
TIME:
|
2:00 p.m.
ET
|
COMPLIMENTARY
REGISTRATION:
|
https://zoom.us/webinar/register/WN_KHDIM1GmQi6On6OA6gAZ6w
|
About The Investor Summit
The Investor Summit
(formerly MicroCap Conference) is an exclusive, independent
conference dedicated to connecting smallcap and microcap companies
with qualified investors. The Q2 Investor Summit will take
place virtually, featuring 80+ companies and over 300 institutional
and retail investors.
Please visit the website at www.investorsummitgroup.com
About Miravo Healthcare
Miravo is a Canadian focused,
healthcare company with global reach and a diversified portfolio of
commercial products. The Company's products target several
therapeutic areas, including pain, allergy, neurology and
dermatology. The Company's strategy is to in-license and
acquire growth-oriented, complementary products for Canadian and
international markets. Miravo's head office is located in
Mississauga, Ontario, Canada, the
international operations are located in Dublin, Ireland and the Company's
manufacturing facility is located in Varennes, Québec, Canada. The
Varennes facility operates in a
Good Manufacturing Practices (GMP) environment respecting the U.S,
Canada and E.U. GMP regulations
and is regularly inspected by Health Canada and the U.S. Food and
Drug Administration. For additional information, please visit
www.miravohealthcare.com.
View original content to download
multimedia:http://www.prnewswire.com/news-releases/miravo-healthcare-to-present-at-q2-virtual-investor-summit-301288267.html
SOURCE Nuvo Pharmaceuticals Inc.